Week in Review: 3SBio Files for $500 Million IPO in Hong Kong

After going private two years ago, 3SBio of Shenyeng plans to IPO in Hong Kong in a transaction that will raise $400-$500 million; Fosun Pharma is rumored to have offered $480 million to acquire Lumenis, an Israeli aesthetic medical device company; WuXi PharmaTech borrowed $165 million from a consortium of banks to expand into new businesses, especially offering personalized medicine diagnostics to China hospitals; Rainbow Medical, an Israeli medical device incubator, raised $25 million from China investors for its portfolio of 12 medical device companies and opened a Shanghai office to promote collaborations in China; Crown Bioscience, a US-China preclinical CRO with a focus on oncology, acquired diagnostic oncology assets from Molecular Response of San Diego; and in an exclusive interview with ChinaBio® Today, Mark Lotter, Founder and CEO of Nuance Biotech, a Shanghai-based startup, described the company's plan to in-license and develop drugs for markets in China and South Africa. More details.... Stock Symbols: (SHA: 600196; HK: 02196) (NSDQ: LMNS) (NYSE: WX) Share this with colleagues: // //